Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 55

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 55
---
 February 28,
2025, members of management began outreach to firms to provide financial advisory services to assist the Transaction Committee in discharging its mandate.

On March 20, 2025, following the termination of development for lunresertib and camonsertib combination therapy for multiple tumor types,
the Transaction Committee passed a unanimous written consent approving the engagement of Leerink Partners as financial advisor to explore strategic alternatives, including a sale, merger, or other transaction. The Transaction Committee selected
Leerink Partners to be its financial advisor based upon, among other factors, Leerink Partners’ reputation, its experience advising companies in connection with strategic

30

review processes similar to the one the Board was considering, and its familiarity with the industry in which the Company operates.

On March 21, 2025, Company management held a meeting with Leerink Partners in connection with various possible strategic transactions
involving the Company, including the sale of the Company or its assets whether by merger, consolidation or other business combination, stock sale, asset sale, exchange or tender offer, a reorganization, recapitalization, the formation of a joint
venture, partnership or similar entity, or otherwise; any so-called “reverse merger” transaction in which the Company effects a business combination with another entity and a result of which, the
Company remains a publicly traded entity with the equity holders of the other entity owning a majority of the outstanding equity of the ongoing public entity; or a liquidation or winding down of the Company.

On March 28, 2025, the Company entered into an engagement letter to formalize the retention of Leerink Partners as the Company’s
financial advisor.

From April to October 2025, Company management, with the assistance of Leerink Partners, conducted a three-pronged
process – pursuing a strategic whole company or asset sale, an orthogonal merger with a high-quality private company, and/or sale to a financial buyer. During this timeframe, at the direction of the Transaction Committee, Leerink Partners and
the Company conducted a series of outreach campaigns to various private and public companies within the biotechnology and pharmaceutical industries to gauge such parties’ interest in a potential strategic transaction with the Company. As a
result of this campaign, during this time, representatives of Leerink Partners and the Company reached out to, or received inbound requests from, 43 strategic and 28 orthogonal merger counterparties to gauge interest in a potential asset sale or
business combination, respectively. In evaluating the inbound requests, the Company received information